Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study
NP Shah, V García-Gutiérrez… - Leukemia & …, 2020 - Taylor & Francis
Abstract Treatment-free remission (TFR) in patients with chronic myeloid leukemia in chronic
phase (CML-CP) is considered a feasible option, especially with the ability of second …
phase (CML-CP) is considered a feasible option, especially with the ability of second …
[引用][C] Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study
NP Shah, V García-Gutiérrez, A Jiménez-Velasco… - Leukemia & …, 2019 - cir.nii.ac.jp
Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable
deep molecular response: the DASFREE study | CiNii Research CiNii 国立情報学研究所 学術情報 …
deep molecular response: the DASFREE study | CiNii Research CiNii 国立情報学研究所 学術情報 …
Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study.
NP Shah, V García-Gutiérrez… - Leukemia & …, 2020 - search.ebscohost.com
Abstract Treatment-free remission (TFR) in patients with chronic myeloid leukemia in chronic
phase (CML-CP) is considered a feasible option, especially with the ability of second …
phase (CML-CP) is considered a feasible option, especially with the ability of second …
Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study
NP Shah, V García-Gutiérrez… - Leukemia & …, 2020 - pubmed.ncbi.nlm.nih.gov
Treatment-free remission (TFR) in patients with chronic myeloid leukemia in chronic phase
(CML-CP) is considered a feasible option, especially with the ability of second-generation …
(CML-CP) is considered a feasible option, especially with the ability of second-generation …
Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study.
NP Shah, V García-Gutiérrez… - Leukemia & …, 2019 - europepmc.org
Treatment-free remission (TFR) in patients with chronic myeloid leukemia in chronic phase
(CML-CP) is considered a feasible option, especially with the ability of second-generation …
(CML-CP) is considered a feasible option, especially with the ability of second-generation …
Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study
NP Shah, V García-Gutiérrez… - LEUKEMIA & …, 2020 - iris.unina.it
Treatment-free remission (TFR) in patients with chronic myeloid leukemia in chronic phase
(CML-CP) is considered a feasible option, especially with the ability of second-generation …
(CML-CP) is considered a feasible option, especially with the ability of second-generation …